门静脉化疗栓塞预防肝癌切除术后复发的临床分析

目的 探讨原发性肝细胞癌切除术后,经皮经肝门静脉穿刺化疗栓塞(PVCE)预防肿瘤复发的效果.方法 回顾性分析我院2007年1月至2010年1月89例肝癌手术切除患者临床资料.其中术后进行预防性经皮经肝门静脉穿刺化疗栓塞(治疗组)41例,未行预防性门静脉化疗栓塞(对照组)48例.随访术后肿瘤复发情况,应用Kaplan-Meier方法分析两组累积无瘤生存率.组间比较用对数秩检验.采用Cox风险比例模型进行多因素分析,筛选出独立预后因素.结果 术后随访6～42个月.治疗组患者术后1年及2年无瘤生存率分别为76.5％、48.0％,对照组分别为53.8％、25.8％,差异有统计学意义(P＜0.05)；平均无瘤生存期分别为19.91个月(95％CI,16.09～23.73)和13.80个月(95％ CI,10.95～16.65),治疗组累积无瘤生存率高于对照组(P=0.01).Cox模型多因素分析显示:预防性门静脉化疗栓塞、肿瘤大小、术前门静脉癌栓、术后经导管动脉化疗栓塞(TACE)是影响患者肝癌切除术后复发的独立因素.结论 肝癌切除术后经皮经肝门静脉穿刺化疗栓塞能有效预防肿瘤复发.

Adjuvant portal vein chemoembolization in partial hepatectomy for hepatocellular carcinoma

Objective To study the efficacy of adjuvant percutaneous transhepatic portal vein chemoembolization (PVCE) in the prevention of tumor recurrence after partial hepatectomy for hepatocellular carcinoma.Methods The clinical data of 89 patients who received liver resection for hepatocellular carcinoma in our hospital from January 2007 to January 2010 were studied retrospectively.41patients received PVCE (the treatment group) while 48 patients received no PVCE (the control group).Postoperative recurrence and cumulative disease free survivals were compared using the Kaplan-Meier method.Results On follow-up which ranged from 6-42 months,the 1- and 2-year disease free survivals were 76.5％ and 48.0％ in the treatment group,and 53.8％ and 25.8％ respectively in the control group (P＜0.05).The mean disease free survivals were 19.91 (95％ CI,16.09-23.73)and 13.8 months (95 ％ CI,10.95-16.65),respectively.The cumulative disease free survivals in the PVCE group were significantly higher than the control group (P=0.01).Cox multivariate analysis showed that adjuvant PVCE,tumor size,portal vein thrombosis,and postoperative transcatheter arterial chemoembolization (TACE) were independent factors of disease free survival.Conclusion Adjuvant PVCE was effective in preventing postoperative recurrence of hepatocellular carcinoma after partial hepatectomy.